Envveno Medical's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Envveno Medical's ROA in the second quarter of 2026?
Envveno Medical Corporation recorded a cumulative net loss of $-16 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -57.09%.

However, within the Healthcare sector 597 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4035, from total ROA ranking in the first quarter of 2026 at 4660.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-39.42 %	-35.69 %	-34.24 %	-35.8 %	-10.78 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-16	-19	-19	-22	-23
Return On Assets (TTM)	-57.09 %	-60.42 %	-56.01 %	-56.88 %	-53.49 %
NVNO's Total Ranking	# 4035	# 4660	# 4092	# 4107	# 4129
Total Assets (TTM) in million	22	26	30	32	37
Seq. Total Assets Change	-15.09 %	-11.72 %	-8.62 %	-11.55 %	-9.86 %
Seq. Net Income Change	-	-	-	-	-

NVNO's 5 Years Annual ROA >> Back to NVNO Management Effectiveness >> Compare NVNO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 148
Sector	# 598
Overall	# 3965

Return On Assets Statistics
High	Average	Low
-17.23 %	-74.93 %	-175.73 %
(Jun 30 2018)		(Jun 30 2020)

Financial Statements
Envveno Medical's Assets	$ 22 million	NVNO's Balance sheet
Envveno Medical's Income	$ -4 million	Quarterly NVNO's Income Statement
NVNO's Income by Division		See NVNO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-34.24 %	-6.84 %	17.82 %	-27.71 %	437.66 %
Total Assets in million	30	45	48	41	57
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	-22	-24	-25	-17
Annual Return On Assets	-65.87 %	-48.54 %	-48.73 %	-60.23 %	-29.17 %

NVNO's 5 Years Annual ROA >> Back to NVNO Management Effectiveness >> Compare NVNO ROA to its Competitors

More Return On Assets Ratios
NVNO's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NVNO's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NVNO's Competitors
Subscribers only: Roa for Envveno Medical's Suppliers
Subscribers only: Return On Assets for NVNO's Customers

You may also want to know
NVNO's Roi	NVNO's Inventory Turnover Ratio	NVNO's Growth Rates	NVNO's Dividend Comparisons
	NVNO's Profitability Ratios	NVNO's Asset Turnover Ratio	NVNO's Dividend Growth
NVNO's Roe	NVNO's Valuation Ratios	NVNO's Financial Strength Ratios	NVNO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T18:45:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.